TB-500: How It Works, Dosing, and the Evidence

TB-500 is one of the most popular "healing" peptides, usually mentioned in the same breath as BPC-157. It also comes wrapped in more confident marketing than its human evidence supports, and there's a naming sleight-of-hand worth understanding before anything else.

TB-500 is a synthetic peptide based on the active region of thymosin beta-4, used for healing and recovery — and it isn't quite the same molecule the clinical research studied. Here's what it actually is, how it's thought to work, and where the evidence is real versus extrapolated.

Quick Reference

What TB-500 Actually Is

This is the part the marketing blurs. Thymosin beta-4 is a naturally occurring 43-amino-acid protein found throughout the body. It plays a central role in regulating actin — a building-block protein critical to cell structure and movement — and through that, it's involved in cell migration, blood-vessel formation, and wound healing.

TB-500 is a synthetic peptide built around thymosin beta-4's key functional fragment — the actin-binding region (the sequence often written LKKTETQ). It's designed to reproduce the active part without being the entire natural protein.

Why this matters: vendors routinely label TB-500 as "thymosin beta-4," and they're not entirely the same thing. The bulk of the published clinical and human research used full-length thymosin beta-4, not the TB-500 fragment sold for recovery. So when a product page cites impressive "thymosin beta-4 studies," it's borrowing the credibility of a molecule that isn't exactly what's in the vial.

How It's Thought to Work

The proposed mechanisms are well-characterized at the cellular level:

• Actin regulation. By binding actin, it supports the cell movement that tissue repair depends on.
• Cell migration. It's thought to help the cells involved in healing travel to where they're needed.
• Angiogenesis. It promotes the formation of new blood vessels, which can support repair in damaged tissue.
• Anti-inflammatory effects. It appears to modulate inflammation, part of the rationale for recovery use.

A practical consequence of this mechanism: TB-500 is generally believed to act systemically — circulating through the body — rather than only where it's injected. That's a meaningful contrast with how some people use BPC-157 (injected near an injury site), and it's why TB-500 is typically injected anywhere subcutaneously.

The Evidence — Honestly

Here's where it pays to separate mechanism from proof.

Strong: mechanism and animal data. The cellular role of thymosin beta-4 is genuinely well-established, and there's a substantial body of animal and preclinical research — including studies in cardiac repair, wound healing, and veterinary use in horses, where it's been used for soft-tissue injury.

Real but different molecule: human thymosin beta-4 work. Full-length thymosin beta-4 has been investigated in human trials for things like wound healing, dry-eye disease, and cardiac repair. That research is legitimate — but again, it studied the full protein, not the TB-500 fragment.

Thin: human evidence for TB-500 itself. TB-500 as sold and used for athletic recovery has essentially no controlled human trials behind it. The healing claims you'll see rest on mechanism plus animal data plus extrapolation from thymosin beta-4 — not on human outcome studies of TB-500.

None of that means it doesn't work; it means the honest status is "plausible mechanism, strong animal data, unproven in humans." That's a very different thing from "clinically proven," and worth holding onto when you read confident before-and-after claims.

Banned in Sports

If you're a tested athlete, this is non-negotiable: WADA prohibits TB-500 and thymosin beta-4 at all times, in and out of competition, under the peptide growth-factor category of the prohibited list. It will cause a doping violation. Treat it accordingly.

TB-500 vs BPC-157

These two are the core of the "healing peptide" conversation and are frequently stacked together — the so-called Wolverine stack — on the theory that they work through complementary mechanisms:

• TB-500 acts on actin and cell migration, with systemic, whole-body effects.
• BPC-157 is a fragment of a gastric protein, thought to work more locally on angiogenesis and tissue protection.

The case for combining them is mechanistic, not proven by head-to-head human trials. We've laid out the full comparison in BPC-157 vs TB-500, the stack evidence in the Wolverine stack guide, and BPC-157's own dosing in the BPC-157 dosage guide. The short version: both are popular, both lean heavily on animal data, and BPC-157 has a handful of small human studies while TB-500 has essentially none.

How It's Used

TB-500 is supplied as a lyophilized powder that's reconstituted with bacteriostatic water and injected subcutaneously. Because it's thought to act systemically, injection-site choice is less about targeting an injury and more about rotating sites comfortably.

Community protocols commonly describe two phases:

• A "loading" phase — higher, more frequent dosing over the first several weeks.
• A "maintenance" phase — a lower dose at a longer interval afterward.

Be clear-eyed about what that is: a community convention, not a validated schedule. There is no approved human dosing for TB-500, so the loading/maintenance pattern is something people share, not something trials established. Getting the reconstitution and dose math right still matters regardless — see the peptide reconstitution guide and the bacteriostatic water guide.

Dosing

We won't print a microgram protocol, because there isn't a validated one and copying a number off a vendor's card isn't a substitute for a provider. Two honest framing points instead:

• The loading/maintenance structure is the convention, but the specific amounts vary widely between sources and aren't backed by human dosing studies.
• Storage affects whether it's doing anything. Reconstituted TB-500 is refrigerated and time-limited; handling errors degrade it. The peptide storage guide covers shelf life after mixing.

Side Effects and the Angiogenesis Caution

Reported side effects are generally mild: temporary fatigue or lethargy after injection, a head-rush sensation, and injection-site reactions. Human safety data is limited, so "generally well tolerated in reports" is the honest ceiling — not "proven safe."

One mechanism-based caution deserves a plain statement: TB-500 promotes angiogenesis, the growth of new blood vessels. The same property that could help deliver blood to healing tissue is, in theory, unwelcome anywhere you wouldn't want to feed tissue growth. This is a theoretical concern rather than a documented outcome in users, but it's a real reason that anyone with a history of cancer, or other relevant risk factors, should not treat this as casual — and should talk to a physician first.

Sourcing and Legality

The standard research-peptide reality applies: TB-500 is sold as a "research chemical," often labeled "not for human consumption," with no guarantee of purity or that the vial contains the dose on the label. We don't recommend suppliers. It is not an approved human drug, and its legal status sits in the research-chemical gray zone. Combined with the WADA ban and the thin human evidence, the sensible path is a conversation with a knowledgeable provider rather than a vendor.

Tracking TB-500

If you're running TB-500 — especially on a loading-then-maintenance pattern, or stacked with BPC-157 — the dates, doses, sites, and how you feel after each injection are exactly the details that blur together without a record. Logging them makes the phase transitions clean and gives you real data instead of a guess about what you did three weeks ago.

Done Dose tracks injectable peptides like this in one place — dose, timing, site rotation, and a reviewable history. For multi-peptide stacks, the best peptide tracker app comparison covers how the options handle running more than one at once. Set it up in under a minute.